BTIG Maintains a Buy Rating on Avita Medical (RCEL)

By Jason Carr

BTIG analyst Ryan Zimmerman maintained a Buy rating on Avita Medical (RCELResearch Report) today and set a price target of $41.00. The company’s shares closed last Friday at $21.07.

According to, Zimmerman is a top 100 analyst with an average return of 37.5% and a 66.9% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Organogenesis Holdings, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Avita Medical is a Moderate Buy with an average price target of $34.00.

See today’s analyst top recommended stocks >>

Avita Medical’s market cap is currently $523.4M and has a P/E ratio of 1.20. The company has a Price to Book ratio of 8.83.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Avita Medical Ltd. engages in the development and distribution of regenerative and respiratory medicine and treatments. It operates through the following segments: Asia Pacific, Europe, and Americas. The Asia Pacific, Europe, and Americas segments involve in the sale of RECELL Devices. The company was founded on December 21, 1992 and is headquartered in Royston, the United Kingdom.